华森制药(002907) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥230,001,139.60, representing a 34.88% increase compared to ¥170,526,616.65 in the same period last year[9]. - Net profit attributable to shareholders for Q1 2021 was ¥36,473,743.54, up 30.98% from ¥27,846,825.73 in the previous year[9]. - The net profit after deducting non-recurring gains and losses was ¥35,346,886.09, reflecting a 38.59% increase from ¥25,504,415.52 year-on-year[9]. - Basic earnings per share for Q1 2021 were ¥0.0911, which is a 30.89% increase from ¥0.0696 in the previous year[9]. - The company reported a net profit margin improvement, with net profit for the quarter showing a significant increase compared to the previous year[67]. - The total profit for the current period was ¥42,655,085.41, up from ¥32,750,236.58 in the previous period, indicating strong overall performance[74]. Cash Flow - The net cash flow from operating activities reached ¥17,248,596.47, a significant increase of 90.05% compared to ¥9,075,927.29 in the same period last year[9]. - Cash flow from operating activities saw a significant increase of 90.05%, reaching CNY 17,248,596.47, attributed to higher sales collections and reduced sales expenses[32]. - The cash flow from operating activities was ¥151,995,434.30, compared to ¥145,064,102.39 in the previous period, showing a positive trend in cash generation[82]. - Operating cash inflow totaled ¥155,786,643.10, an increase from ¥150,568,616.49 in the previous period[86]. - Total cash inflow from operating activities was ¥141,066,440.95, slightly down from ¥147,541,652.54[89]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,753,552,889.22, marking a 1.87% increase from ¥1,721,413,431.40 at the end of the previous year[9]. - The total assets of the company reached approximately ¥1.75 billion, up from ¥1.72 billion, indicating a growth of around 1.9%[56]. - The company's total liabilities were approximately ¥534.24 million, a slight decrease from ¥539.59 million, indicating a reduction of about 1%[54]. - Total liabilities reached CNY 524,573,753.02, compared to CNY 516,590,007.72 in the previous period, indicating a slight increase of 1.9%[64]. - The company's equity attributable to shareholders reached approximately ¥1.22 billion, an increase from ¥1.18 billion, reflecting a growth of about 3.5%[56]. Research and Development - Research and development expenses increased by 35.83% to CNY 6,611,832.82, reflecting the company's commitment to enhancing R&D investments[29]. - Research and development expenses for the quarter were CNY 6,611,832.82, up from CNY 4,867,581.50, representing a growth of approximately 36%[67]. Government Subsidies and Other Income - The company received government subsidies amounting to ¥1,382,781.42 during the reporting period[9]. - The company’s other income increased by 44.90% to CNY 1,588,496.07, mainly due to an increase in government subsidies[29]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,419[14]. - The company reported no significant non-operating fund occupation by controlling shareholders or related parties during the reporting period[43]. Investment and Financing Activities - The company reported a 91.66% decrease in short-term borrowings, down to CNY 1,000,901.39, due to the repayment of a substantial portion of bank loans[29]. - Cash inflow from financing activities was ¥6,000,000.00, while cash outflow totaled ¥11,151,435.84, leading to a net cash flow of -¥11,151,435.84[88]. Inventory and Receivables - The accounts receivable increased to approximately ¥202.74 million from ¥167.12 million, representing a significant rise of about 21.3%[48]. - Inventory levels increased to CNY 107,647,104.84 from CNY 105,927,369.21, indicating a slight rise of 1.1%[58]. Taxation - The company reported a tax expense of ¥6,181,341.87, which is higher than the previous period's ¥4,903,410.85, reflecting increased profitability[74]. - The company reported a 72.18% increase in taxes payable, amounting to CNY 14,135,020.06, primarily due to the accrual of income tax for the first quarter[29]. Other Information - The first quarter report for 2021 was not audited[107]. - The company has not engaged in any major contracts or significant external guarantees during the reporting period[43][54].